The pharmacological management of asthma in adults: 2023 update

References

• Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2022;59(1):2102730. doi: 10.1183/13993003.02730-2021
   PubMed Web of Science ®Google Scholar
• Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: a report from the National asthma education and prevention program coordinating committee expert panel working group. J Allergy Clin Immunol. 2020;146(6):1217–1270. doi: 10.1016/j.jaci.2020.10.003
   PubMed Web of Science ®Google Scholar
• Krishnan JA, Cloutier MM, Schatz M. National asthma education and prevention program 2020 guideline update: where do we go from here? Am J Respir Crit Care Med. 2021;203(2):164–167. doi: 10.1164/rccm.202011-4236ED
   PubMed Web of Science ®Google Scholar
• Niimi A, Fukunaga K, Taniguchi M, et al. Executive summary: Japanese guidelines for adult asthma (JGL) 2021. Allergol Int. 2023;72(2):207–226. doi: 10.1016/j.alit.2023.02.006
   PubMed Web of Science ®Google Scholar
• Rhee CK, Moon JY, Joo H, et al. Summary of Korean asthma guideline. Tuberc Respir Dis (Seoul). 2023;86(3):158–165. doi: 10.4046/trd.2023.0052
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Criée CP, de Jong CCM, et al. S2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023. Pneumologie. 2023;77(8):461–543. doi: 10.1055/a-2070-2135
   PubMedGoogle Scholar
• Plaza Moral V, Alobid I, Álvarez Rodríguez C, et al. GEMA 5.3. Spanish guideline on the management of asthma. Open Respir Arch. 2023;5(4):100277. doi: 10.1016/j.opresp.2023.100277
   PubMedGoogle Scholar
• Raherison-Semjen C, Guilleminault L, Billiart I, et al. Updated guidelines (2021) for management and follow-up of asthmatic patients of the French society of pneumology (SPLF) and the French society of pediatric pneumology and allergology (SP2A). Short version. Respir Med Res. 2022;81:100898. doi: 10.1016/j.resmer.2022.100898
   PubMedGoogle Scholar
• Al-Moamary MS, Alhaider SA, Alangari AA, et al. The Saudi initiative for asthma - 2021 update: guidelines for the diagnosis and management of asthma in adults and children. Ann Thorac Med. 2021;16(1):4–56. doi: 10.4103/atm.ATM_697_20
   PubMed Web of Science ®Google Scholar
• National Asthma Council Australia. Australian asthma handbook. Version 2.1. Melbourne: National Asthma Council Australia; 2020. Available from: http://www.asthmahandbook.org.au.
   Google Scholar
• National Institute for Health and Care Excellence. NICE guideline NG80. Asthma: diagnosis, monitoring and chronic asthma management. 2017 Mar 22 [cited 2021 Nov 29]. Available from: https://www.nice.org.uk/guidance/ng80
   Google Scholar
• Larenas-Linnemann D, Salas-Hernández J, Del Río-Navarro BE, et al. MIA 2021, manejo integral del Asma. Lineamientos para méxico. Rev Alerg Mex. 2021;68(Suppl 5):s1–s122.
   PubMedGoogle Scholar
• British Thoracic Society. Update on the BTS/SIGN/NICE joint guideline for the diagnosis, monitoring and management of chronic asthma, Available from: https://www.brit-thoracic.org.uk/news/2023/update-on-the-bts-sign-nice-joint-guideline-for-the-diagnosis-monitoring-and-management-of-chronic-asthma/.
   Google Scholar
• Bateman ED, O’Byrne PM, FitzGerald JM, et al. Positioning as-needed budesonide-formoterol for mild asthma: effect of prestudy treatment in pooled analysis of SYGMA 1 and 2. Ann Am Thorac Soc. 2021;18(12):2007–2017.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ritondo BL, Ora J, et al. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. Eur Respir J. 2020;56(3):2000625. doi: 10.1183/13993003.00625-2020
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Matera MG, et al. Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023;62(2):2300700. doi: 10.1183/13993003.00700-2023
   PubMed Web of Science ®Google Scholar
• Pavord ID, Tran TN, Jones RC, et al. Effect of stepping up to high-dose inhaled corticosteroids in patients with asthma: UK database study. J Allergy Clin Immunol Pract. 2023;11(2):532–543. doi: 10.1016/j.jaip.2022.10.040
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ritondo BL, Calzetta L. Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. Eur Respir J. 2021;58(3):2004233. doi: 10.1183/13993003.04233-2020
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Brusselle GG, Levy ML, et al. A2BCD: a concise guide for asthma management. Lancet Respir Med. 2023;11(6):573–576. doi: 10.1016/S2213-2600(22)00490-8
   PubMed Web of Science ®Google Scholar
• Truong-Thanh T, Vo-Thi-Kim A, Vu-Minh T, et al. The beneficial role of FeNO in association with GINA guidelines for titration of inhaled corticosteroids in adult asthma: a randomized study. Adv Med Sci. 2020;65(2):244–251. doi: 10.1016/j.advms.2020.03.001
   PubMed Web of Science ®Google Scholar
• Boer S, Honkoop PJ, Loijmans RJB, et al. Personalised exhaled nitric oxygen fraction (FENO)-driven asthma management in primary care: a FENO subgroup analysis of the ACCURATE trial. ERJ Open Res. 2020;6(3):00351–2019. doi: 10.1183/23120541.00351-2019
   PubMedGoogle Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention (2023 update). Available from: https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Full-report-23_07_06-WMS.pdf.
   Google Scholar
• Chauhan BF, Jeyaraman MM, Singh Mann A, et al. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Cochrane Database Syst Rev. 2017;2017(4):CD010347.
   Google Scholar
• Wang X, Luo J, Wang D, et al. The efficacy and safety of long-term add-on treatment of azithromycin in asthma: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(38):e17190. doi: 10.1097/MD.0000000000017190
   PubMed Web of Science ®Google Scholar
• Choi Y, Lim HS, Chung D, et al. Risk evaluation of azithromycin-induced QT prolongation in real-world practice. Biomed Res Int. 2018;2018:1574806. doi: 10.1155/2018/1574806
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA drug safety communication: azithromycin (zithromax or Zmax) and the risk of potentially fatal heart rhythms. 2013. Available from: http://www.fda.gov/drugs/drugsafety/ucm341822.htm.
   Google Scholar
• Taylor SL, Leong LEX, Mobegi FM, et al. Long-term azithromycin reduces Haemophilus influenzae and increases antibiotic resistance in severe asthma. Am J Respir Crit Care Med. 2019;200(3):309–317. doi: 10.1164/rccm.201809-1739OC
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Naviglio S, et al. An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. Expert Opin Pharmacother. 2022;23(10):1205–1216. doi: 10.1080/14656566.2022.2083955
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201(3):276–293. doi: 10.1164/rccm.201904-0903SO
   PubMed Web of Science ®Google Scholar
• Chung LP, Upham JW, Bardin PG, et al. Rational oral corticosteroid use in adult severe asthma: a narrative review. Respirology. 2020;25(2):161–172. doi: 10.1111/resp.13730
   PubMed Web of Science ®Google Scholar
• Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. doi: 10.1136/bmj.j1415
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764–770. doi:10.7326/0003-4819-141-10-200411160-00007
   PubMed Web of Science ®Google Scholar
• van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016–1020.
   PubMedGoogle Scholar
• Varas-Lorenzo C, Rodriguez LA, Maguire A, et al. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007;192(2):376–383.
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Duh MS, Lafeuille MH, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol. 2015;136(6):1488–1495.
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European respiratory society/American thoracic society guideline. Eur Respir J. 2020;55(1):1900588. doi: 10.1183/13993003.00588-2019
   PubMed Web of Science ®Google Scholar
• Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines - recommendations for severe asthma. Allergy. 2021;76(1):14–44.
   PubMed Web of Science ®Google Scholar
• Israel E. Implementing the guidelines: what do you do when the rubber hits the road? J Allergy Clin Immunol. 2020;146(6):1271–1274. doi: 10.1016/j.jaci.2020.10.010
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Matera MG, et al. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2020;6(1):47–66. doi: 10.1007/s41030-019-00109-1
   PubMedGoogle Scholar
• Shah PA, Brightling C. Biologics for severe asthma - which, when and why? Respirology. 2023;28(8):709–721. doi: 10.1111/resp.14520
   PubMed Web of Science ®Google Scholar
• Ricciardolo FLM, Carriero V, Bertolini F. Which therapy for non-Type(T)2/T2-low asthma. J Pers Med. 2021;12(1):10. doi: 10.3390/jpm12010010
   PubMed Web of Science ®Google Scholar
• Schmitt J, Wüstenberg E, Küster D, et al. The moderating role of allergy immunotherapy in asthma progression: results of a population-based cohort study. Allergy. 2020;75(3):596–602. doi: 10.1111/all.14020
   PubMed Web of Science ®Google Scholar
• Zielen S, Devillier P, Heinrich J, et al. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2018;73(1):165–177. doi: 10.1111/all.13213
   PubMed Web of Science ®Google Scholar
• Wahn U, Bachert C, Heinrich J, et al. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Allergy. 2019;74(3):594–604. doi: 10.1111/all.13598
   PubMed Web of Science ®Google Scholar
• Levy ML, Bacharier LB, Bateman E, et al. Key recommendations for primary care from the 2022 global initiative for asthma (GINA) update. NPJ Prim Care Respir Med. 2023;33(1):7. 1. doi: 10.1038/s41533-023-00330-1
   Web of Science ®Google Scholar
• Papi A, Chipps BE, Beasley R, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma. N Engl J Med. 2022;386(22):2071–2083. doi: 10.1056/NEJMoa2203163
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA approves drug combination treatment for adults with asthma. 2023. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-combination-treatment-adults-asthma.
   Google Scholar
• Venkatesan P. 2023 GINA report for asthma. Lancet Respir Med. 2023;11(7):589. doi: 10.1016/S2213-2600(23)00230-8
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Buhl R, Canonica GW, et al. Pioneering a paradigm shift in asthma management: remission as a treatment goal. Lancet Respir Med. 2023;12(2):96–99. doi: 10.1016/S2213-2600(23)00415-0
   PubMed Web of Science ®Google Scholar
• Canonica GW, Blasi F, Carpagnano GE, et al. Severe asthma network Italy definition of clinical remission in severe asthma: a delphi consensus. J Allergy Clin Immunol Pract. 2023;11(12):3629–3637. doi: 10.1016/j.jaip.2023.07.041
   PubMed Web of Science ®Google Scholar
• McDowell PJ, McDowell R, Busby J, et al. Clinical remission in severe asthma with biologic therapy: an analysis from the UK severe asthma registry. Eur Respir J. 2023;62(6):2300819. doi: 10.1183/13993003.00819-2023
   PubMed Web of Science ®Google Scholar
• Quarato CMI, Tondo P, Lacedonia D, et al. Clinical remission in patients affected by severe eosinophilic asthma on dupilumab therapy: a long-term real-life study. J Clin Med. 2024;13(1):291. doi: 10.3390/jcm13010291
   PubMed Web of Science ®Google Scholar
• Nolasco S, Crimi C, Campisi R. Personalized medicine in asthma: current approach and future perspectives. J Pers Med. 2023;13(10):1459. doi: 10.3390/jpm13101459
   PubMed Web of Science ®Google Scholar
• Domingo C, Singh D. The changing asthma management landscape and need for appropriate SABA prescription. Adv Ther. 2023;40(4):1301–1316.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–1876.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–1887.
   PubMed Web of Science ®Google Scholar
• Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–2030.
   PubMed Web of Science ®Google Scholar
• Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–928. doi: 10.1016/S0140-6736(19)31948-8
   PubMed Web of Science ®Google Scholar
• Pavord ID, Barnes PJ, Lemière C, et al. Diagnosis and assessment of the asthmas. J Allergy Clin Immunol Pract. 2023;11(1):1–8. doi: 10.1016/j.jaip.2022.09.034
   PubMed Web of Science ®Google Scholar
• Cazzola M, Braido F, Calzetta L, et al. The 5T approach in asthma: triple therapy targeting treatable traits. Respir med. 2022;200:106915. doi: 10.1016/j.rmed.2022.106915.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Matera MG. Might it be appropriate to anticipate the use of long-acting muscarinic antagonists in asthma? Drugs. 2023;83(11):957–965. doi: 10.1007/s40265-023-01897-2
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Matera MG. The latest on the role of LAMAs in asthma. J Allergy Clin Immunol. 2020;146(6):1288–1291. doi: 10.1016/j.jaci.2020.06.014
   PubMed Web of Science ®Google Scholar
• Kistemaker LEM, Prakash YS. Airway innervation and plasticity in asthma. Physiology. 2019;34(4):283–298. doi: 10.1152/physiol.00050.2018
   PubMed Web of Science ®Google Scholar
• Matera MG, Ora J, Rogliani P, et al. An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma. Expert Opin Drug Discov. 2023;18(9):951–963. doi: 10.1080/17460441.2023.2230885
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022;10(7):650–660. doi: 10.1016/S2213-2600(21)00537-3
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi: 10.1056/NEJMoa2034975
   PubMed Web of Science ®Google Scholar
• Lipworth B, Chan R. Disconnect for tezepelumab on exacerbations, symptoms, and quality of life in type 2 low asthma. Am J Respir Crit Care Med. 2023;208(2):211. doi: 10.1164/rccm.202304-0746LE
   PubMed Web of Science ®Google Scholar
• Shrimanker R, Keene O, Hynes G, et al. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med. 2019;200(10):1308–1312. doi: 10.1164/rccm.201903-0599LE
   PubMed Web of Science ®Google Scholar
• Couillard S, Pavord ID, Heaney LG, et al. Sub-stratification of type-2 high airway disease for therapeutic decision-making: a ‘bomb’ (blood eosinophils) meets ‘magnet’ (FeNO) framework. Respirology. 2022;27(8):573–577. doi: 10.1111/resp.14294
   PubMed Web of Science ®Google Scholar
• Rupani H, Hew M. Super-responders to severe asthma treatments: defining a new paradigm. J Allergy Clin Immunol Pract. 2021;9(11):4005–4006. doi: 10.1016/j.jaip.2021.08.014
   PubMed Web of Science ®Google Scholar
• Portacci A, Dragonieri S, Carpagnano GE. Super-responders to biologic treatment in type 2-high severe asthma: passing fad or a meaningful phenotype? J Allergy Clin Immunol Pract. 2023;11(5):1417–1420. doi: 10.1016/j.jaip.2023.01.021
   PubMed Web of Science ®Google Scholar
• Novosad J, Krčmová I, Souček O, et al. Subsets of eosinophils in asthma, a challenge for precise treatment. Int J Mol Sci. 2023;24(6):5716. doi: 10.3390/ijms24065716
   PubMed Web of Science ®Google Scholar
• Mtibaa M, Gupta S, Muthukumar M, et al. Cost-effectiveness of once-daily, single-inhaler indacaterol acetate/glycopyrronium bromide/mometasone furoate in patients with uncontrolled moderate-to-severe asthma in Canada. Clinicoecon Outcomes Res. 2021;13:957–967. doi: 10.2147/CEOR.S336915
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri L, Lahousse L, et al. Single inhaler triple therapy (SITT) in asthma: systematic review and practice implications. Allergy. 2022;77(4):1105–1113. doi: 10.1111/all.15076
   PubMed Web of Science ®Google Scholar
• Busse WW, Abbott CB, Germain G, et al. Adherence and persistence to single-inhaler versus multiple-inhaler triple therapy for asthma management. J Allergy Clin Immunol Pract. 2022;10(11):2904–2913.e6. doi: 10.1016/j.jaip.2022.06.010
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Rogliani P, et al. Step-up and step-down approaches in the treatment of asthma. Expert Rev Respir Med. 2021;15(9):1159–1168. doi: 10.1080/17476348.2021.1935245
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rinaldi B, et al. Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings. Expert Rev Respir Med. 2022;16(11–12):1205–1212. doi: 10.1080/17476348.2023.2167715
   PubMed Web of Science ®Google Scholar
• Lavorini F, Bianco A, Blasi F, et al. What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis. Respir med. 2020;166:105937. doi: 10.1016/j.rmed.2020.105937
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Cavalli F, et al. Treatable mechanisms in asthma. Mol Diagn Ther. 2021;25(2):111–121. doi: 10.1007/s40291-021-00514-w
   PubMed Web of Science ®Google Scholar
• Jellesmark Jensen T, Larsson J, Mäenpää J, et al. AZD4604, an inhaled, selective JAK1 inhibitor reduces fractional exhaled nitric oxide in patients with mild asthma; a randomized, single-blind phase 1 study. J Allergy Clin Immunol. 2024;153(2):AB98. doi: 10.1016/j.jaci.2023.11.323
   Google Scholar
• Obrien C, Morgan F, Wood N, et al. Safety and pharmacokinetics of single ascending doses of KN-002 in healthy volunteers and multiple ascending doses of KN-002 in subjects with mild asthma. J Allergy Clin Immunol. 2024;153(2):AB142. doi: 10.1016/j.jaci.2023.11.470
   Google Scholar
• Davidescu L, Ursol G, Korzh O, et al. Efficacy and safety of masitinib in corticosteroid-dependent severe asthma: a randomized placebo-controlled trial. J Asthma Allergy. 2022;15:737–747. doi: 10.2147/JAA.S337284.
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Wenzel SE, Bozik ME, et al. Safety and efficacy of dexpramipexole in eosinophilic asthma (EXHALE): a randomized controlled trial. J Allergy Clin Immunol. 2023;152(5):1121–1130.e10. doi: 10.1016/j.jaci.2023.05.014
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Tozorakimab. Anti-IL-33 monoclonal antibody, treatment of COPD and asthma, treatment of atopic dermatitis, treatment of diabetic kidney disease. Drugs Future. 2023;48(2):101–109. doi: 10.1358/dof.2023.48.2.3474010
   Web of Science ®Google Scholar
• Clarke AW, Poulton L, Shim D, et al. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. MAbs. 2018;10(4):664–677. doi: 10.1080/19420862.2018.1440164
   PubMed Web of Science ®Google Scholar
• Raphael G, Damera G, Angeles T, et al. TEV-48574, an anti-TL1A antibody in development for use in IBD, is safe and well tolerated following. J Crohns Colitis. 2024;18(suppl.1):i1908.
   Google Scholar
• Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50(4):975–991. doi: 10.1016/j.immuni.2019.03.018
   PubMed Web of Science ®Google Scholar
• Sardon-Prado O, Diaz-Garcia C, Corcuera-Elosegui P, et al. Severe asthma and biological therapies: now and the future. J Clin Med. 2023;12(18):5846. doi: 10.3390/jcm12185846
   PubMed Web of Science ®Google Scholar
• McDonald VM, Fingleton J, Agusti A, et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits down under international workshop report. Eur Respir J. 2019;53(5):1802058. doi: 10.1183/13993003.02058-2018
   PubMed Web of Science ®Google Scholar
• Agusti A, Gibson PG, McDonald VM. Treatable traits in airway disease: from theory to practice. J Allergy Clin Immunol Pract. 2023;11(3):713–723. doi: 10.1016/j.jaip.2023.01.011.
   PubMed Web of Science ®Google Scholar
• McDonald VM, Holland AE. Treatable traits models of care. Respirology. 2024;29(1):24–35. doi: 10.1111/resp.14644
   PubMed Web of Science ®Google Scholar
• Kaplan A, FitzGerald JM, Buhl R, et al. Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management. NPJ Prim Care Respir Med. 2020;30(1):50. doi: 10.1038/s41533-020-00205-9
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Hess DR. Aerosol delivery devices for obstructive lung diseases. Respir Care. 2018;63(6):708–733. doi: 10.4187/respcare.06290
   PubMed Web of Science ®Google Scholar
• Stolbrink M, Thomson H, Hadfield RM, et al. The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review. Lancet Glob Health. 2022;10(10):e1423–e1442. doi: 10.1016/S2214-109X(22)00330-8
   PubMed Web of Science ®Google Scholar
• Cazzola M, Cavalli F, Usmani OS, et al. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Deliv. 2020;17(5):635–646. doi: 10.1080/17425247.2020.1739021
   PubMed Web of Science ®Google Scholar
• Buendía JA, Patiño DG. Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma. BMC Pulm Med. 2021;21(1):397. doi: 10.1186/s12890-021-01775-1
   PubMed Web of Science ®Google Scholar
• Mortimer K, Reddel HK, Pitrez PM, et al. Asthma management in low and middle income countries: case for change. Eur Respir J. 2022;60(3):2103179. doi: 10.1183/13993003.03179-2021
   PubMed Web of Science ®Google Scholar